Clinical Trial Update: A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. [Phase 1, Phase 2]

View source ↗

Summary

This document describes a randomized Phase 1/2 clinical trial evaluating CM313, a humanized CD38 antibody, for Pemphigus vulgaris; the study is not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus Vulgaris

Drugs mentioned

• CM313

Snippet

Sponsor: Chao Ji | Conditions: Pemphigus Disease, Pemphigus Vulgaris (PV) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING